MOTS-c: Evidence, Mechanism, Dosing & Legal Status

MOTS-c ("mitochondrial open reading frame of the 12S rRNA-c") is a 16-amino-acid mitochondrial-derived peptide marketed as an "exercise mimetic," insulin sensitizer and longevity candidate.1 The rodent findings behind that hype are real and impressive; the human proof is not. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. MOTS-c is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is MOTS-c and how does it work?

MOTS-c is a 16-amino-acid peptide translated from a small open reading frame embedded within the mitochondrial 12S rRNA gene — one of the founding members of the "mitochondrial-derived peptide" (MDP) family, alongside humanin and the SHLP series.1 Because it is mitochondrially encoded, MOTS-c acts as a retrograde signal by which mitochondria communicate metabolic state to the nucleus.

The core mechanism — all of it preclinical — runs through the folate, AICAR and AMPK axis. MOTS-c inhibits the folate cycle at the 5-methyl-tetrahydrofolate step, which throttles de novo purine synthesis and causes accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an established endogenous AMPK activator.1 This lets MOTS-c engage AMP-activated protein kinase without first depleting cellular ATP — the property that makes it attractive as an exercise-mimetic signal active even under nutrient-replete conditions, and it also raises intracellular NAD⁺, potentially engaging SIRT1 upstream of AMPK.1 Downstream, AMPK activation drives GLUT4 expression and glucose uptake in skeletal muscle and increases carnitine-shuttle activity and beta-oxidation, a profile of enhanced lipid utilization.1 Under metabolic stress MOTS-c also translocates to the nucleus and modulates stress-adaptive transcription factors such as NRF2, positioning it as a mitohormetic stress regulator rather than a simple kinase switch.3 A distinct immunometabolic mechanism has also been described, in which MOTS-c binds Raptor to inhibit mTORC1 and promote regulatory T-cell differentiation in a type-1-diabetes model.3 Human pharmacokinetics are essentially absent: reviews explicitly flag that stability and oral bioavailability remain unresolved, and no validated half-life exists.3

What is the evidence by indication?

Every efficacy indication below is supported by animal or in-vitro data only and graded C. The genuinely human data are limited to cross-sectional biomarker associations and the observation that exercise raises endogenous MOTS-c — neither of which demonstrates that administering the peptide benefits people.3

The metabolic and exercise data are the most cited and the most extrapolated. In the foundational study, acute systemic MOTS-c reduced non-fasting glucose and improved glucose tolerance in mice, with a hyperinsulinemic-euglycemic clamp localizing the effect to skeletal-muscle glucose clearance; injections in 12-month-old mice reversed age-dependent muscle insulin resistance.1 In the most striking dataset, intermittent MOTS-c given late in life (at 23.5 months) roughly doubled treadmill running capacity in old mice, who outran untreated middle-aged controls, and improved healthspan.214 In humans, exercise itself induces about a 12-fold rise in skeletal-muscle MOTS-c and a 1.6-fold rise in circulation — establishing it as an exercise-responsive peptide, not proving that injecting it improves performance.2

The human record is otherwise observational. Cross-sectional cohorts show serum MOTS-c is lower in poorly controlled type 2 diabetes and in obese children, and plasma MOTS-c declines progressively with age.3 A 12-week structured exercise program in breast-cancer survivors was studied for its effect on circulating MOTS-c — a biomarker-response study, not a test of MOTS-c as a drug.67 The first controlled efficacy trial, a Phase 2a RCT of subcutaneous MOTS-c in prediabetes and obesity with the Matsuda insulin-sensitivity index at 12 weeks as a co-primary endpoint, is registered as NCT07505745 and began recruiting in February 2026, with no results at the time of writing.5

What doses appear in the literature?

Reported strictly as information, not a protocol — no dose has been validated for human efficacy or safety. Rodent studies used intraperitoneal injection in intermittent regimens (for example, three times per week in the longevity work), but standardized milligram-per-kilogram figures are not reproduced in the review literature.2 The Phase 2a human trial administers a fixed once-daily subcutaneous dose for 12 weeks, followed through Week 16 for safety, though the exact milligram amount is not disclosed in the public registry.5 Anecdotal online "research" use describes subcutaneous self-administration commonly cited around 5 to 10 milligrams per week from lyophilized powder reconstituted with bacteriostatic water — figures that are unverified, have no clinical basis, and originate from products labeled not for human use.8 No pharmacopeial product or validated reconstitution standard exists because MOTS-c is unapproved.8

How safe is MOTS-c?

Controlled human safety data do not exist; USADA notes that no completed clinical trials exist, so safe conditions of use are unknown.8 The first systematic safety capture — treatment-emergent adverse events plus anti-drug-antibody immunogenicity — is an endpoint of the ongoing Phase 2a trial.5 Among online users (uncontrolled, confounded by product quality), reported effects include elevated heart rate or palpitations, injection-site irritation, insomnia and fever.8 The dominant regulator-flagged hazard is contamination, not an intrinsic toxicity: the FDA's 2023 Category-2 placement cited immunogenicity risk for some routes, peptide-related impurities, and inadequate API characterization.10 Mechanistically, additive hypoglycemia is conceivable if combined with insulin or insulin secretagogues, and folate-cycle and nucleotide-pathway interference warrants caution in any rapidly dividing-tissue context, though no carcinogenicity signal has been reported.3 Pregnancy and lactation, active malignancy and renal impairment are sensible exclusions — the Phase 2a trial excludes established diabetes, recent cardiovascular events, eGFR below 60, active malignancy and pregnancy.5

What is the FDA and WADA status in 2026?

MOTS-c is not an FDA-approved drug for any indication and has no NDA or BLA; it is sold "for research use only, not for human use."8 The regulatory timeline is precise: in 2023 the FDA placed MOTS-c among roughly 17–19 peptides in 503A Category 2, citing immunogenicity, impurity and characterization concerns.1012 A guidance effective January 7, 2025 ended the Category 1/2/3 system for newly nominated substances while leaving former Category 2/3 substances prohibited pending action.13 On April 15, 2026, HHS and FDA announced removal of 12 peptides including MOTS-c from Category 2 — attributed to withdrawal of nominations — effective around April 23, 2026.1110 The critical caveat: removal from Category 2 does not authorize compounding; it removes the explicit prohibition designation but does not add MOTS-c to the 503A authorized bulks list, which requires a separate Pharmacy Compounding Advisory Committee review scheduled for July 23, 2026.10 As of mid-2026, pharmacies cannot lawfully compound MOTS-c.

For athletes the picture is unambiguous. MOTS-c has been on the WADA Prohibited List since January 1, 2024, listed by full name under category S4.4.1 (Activators of AMP-activated protein kinase) — prohibited at all times, in and out of competition, with no Therapeutic Use Exemption.89 The status is unchanged for 2026, and it is not a DEA-controlled substance — it is regulated as an unapproved drug, not a scheduled one.8

Bottom line. MOTS-c pairs a biologically compelling mechanism and genuinely striking rodent data with a near-total absence of human proof. The gap between promise and proof is the headline — graded C, legally unsettled, and banned in sport. Regulatory facts here are current as of June 2026; the July 23, 2026 PCAC outcome and the Phase 2a trial results were pending at the time of writing and should be re-verified after those dates.